Loading paragraph...
Today's Biggest Stock Gainers
| Symbol | Name | Last Price | Change | % Change | Volume | Market Cap | 52-Week Range |
|---|---|---|---|---|---|---|---|
| OPTX | Syntec Optics | $3.10 | $1.13 | 57.46% | 37.4M | $73M | $1.02$4.51 |
| TIVC | Tivic Health Systems | $2.17 | $0.36 | 19.86% | 33.3M | $3.2M | $1.47$15.64 |
| JFB | Jfb Construction | $16.00 | $2.18 | 15.77% | 142.2K | $85M | $3.39$23.00 |
| VUZI | Vuzix | $3.25 | $0.34 | 11.51% | 440.4K | $233M | $1.47$5.79 |
| MMLP | Martin Midstream Partners | $2.50 | $0.24 | 10.62% | 31 | $98M | $2.21$4.02 |
| LZM | Lifezone Metals | $4.41 | $0.42 | 10.53% | 1.6K | $334M | $2.90$7.25 |
| SOC | Sable Offshore | $8.39 | $0.79 | 10.38% | 5.6M | $1.1B | $3.72$35.00 |
| NVO | Novo Nordisk | $52.86 | $4.76 | 9.90% | 730.5K | $162B | $43.08$93.80 |
| BBLG | Bone Biologics | $2.06 | $0.19 | 9.89% | 11.5M | $3.4M | $1.30$7.74 |
| CRML | Critical Metals | $8.77 | $0.73 | 9.08% | 60.9K | $946M | $1.23$32.15 |
Related Articles
Featured Article
Prediction: 1 Healthcare Giant Set to Soar in 2026
David Jagielski, CPA|Dec 18, 2025
Novo Nordisk has struggled this past year, but its beaten-down valuation has made it a bargain buy today.
Better Buy in 2026: Novo Nordisk or Intuitive Surgical?
Prosper Junior Bakiny|Dec 18, 2025
These struggling healthcare stocks haven't said their last words.
Better Pharmaceutical Buy: Eli Lilly vs. Novo Nordisk
David Jagielski, CPA|Dec 18, 2025
These two healthcare stocks have strong growth prospects, but they've been going in opposite directions.
Advertisement
2 Predictions for Novo Nordisk in 2026
Prosper Junior Bakiny|Dec 14, 2025
The company's worst days might be behind it.
This Pharmaceutical Giant Fell by 10% After a Setback: Time to Sell the Stock?
Prosper Junior Bakiny|Dec 5, 2025
The issues are piling on for the healthcare leader, but this one is nowhere near insurmountable.
Medicare Just Cut the Price of Wegovy: Should You Sell Novo Nordisk Stock?
Prosper Junior Bakiny|Dec 3, 2025
There is more to this news than meets the eye.
Novo Nordisk's Latest Clinical Result Is Sending the Stock Plunging. Here's What Investors Need to Know.
Rick Orford|Dec 1, 2025
A promising obesity and diabetes drug stumbles in Alzheimer's trials, rattling markets. Did investors overreact, or is this a reset for long-term opportunity?
Why Novo Nordisk Stock Just Hit a 4-Year Low
Matthew Benjamin|Nov 29, 2025
Novo Nordisk's drug trial failure is the latest in a series of 2025 woes for the company.
Novo Nordisk Stock Investors Get Huge News on Drug Trial Results
Parkev Tatevosian, CFA|Nov 28, 2025
Investors will want to see these key developments concerning Novo Nordisk's pipeline of new treatments.
Novo Nordisk Just Took a Big Swing, Slashing Its GLP-1 Drug Prices. Will It Pay Off for the Healthcare Giant?
Justin Pope|Nov 23, 2025
The obesity drug producer has taken some hits throughout the past year, but it is beginning to punch back.
